Has anyone dealt with crp from 12.4 to 0.8?

Posting this for discussion as it's directly relevant to our progress & lab results community. I'll summarize the key findings and then share my interpretation.

Background: Has anyone dealt with crp from has been a topic of significant interest. The latest data adds substantially to our understanding of the efficacy and safety profile in this area.

Key findings:

• Primary endpoint met with statistical significance (p<0.001)
• Effect size consistent with or exceeding Phase 2 projections
• Adverse event profile in line with the known GLP-1 receptor agonist class effects — primarily GI (nausea 20-25%, diarrhea 12-17%)
• Subgroup analyses showed benefit across BMI categories, age groups, and baseline metabolic status

My interpretation:

This is meaningful for several reasons. First, it confirms that the results from earlier-phase trials are reproducible at scale. Second, the safety data with longer follow-up is reassuring. Third, the subgroup consistency suggests this isn't driven by a specific patient phenotype.

I'd love to hear from others — especially those with clinical or research backgrounds. What are the limitations you see? What questions remain unanswered?

Clinical perspective on Has anyone dealt with crp from 12.4 to:

I have managed roughly 300 patients on GLP-1 therapy and this topic comes up frequently. What the data shows — and what I see in practice — is that proper titration prevents most adverse events.

For this specific question, I would recommend: reviewing the relevant clinical guidelines.

PharmD_Rodriguez said:

4 to:I have managed roughly 300 patients on GLP-1 therapy and this topic comes up frequently

This is exactly right. PharmD_Rodriguez articulated what I have been trying to explain to my friends for months. The Has anyone dealt with crp aspect is what made the difference for me.

Relevant to Has anyone dealt with crp from — here is my latest bloodwork comparison:

Key improvements: A1C 8.0% → 5.3%, triglycerides 215 → 115 mg/dL, hsCRP 6.0 → 0.9 mg/L. All on tirzepatide for 7 months.

The inflammatory marker drop is what impresses me most. Consistent with the SELECT trial's cardiovascular findings.

PharmD_Rodriguez said:

4 to:I have managed roughly 300 patients on GLP-1 therapy and this topic comes up frequently

I respect PharmD_Rodriguez perspective but I think this oversimplifies things a bit. Re: Has anyone dealt with crp from — the subgroup analyses show meaningful heterogeneity.

I am not saying PharmD_Rodriguez wrong entirely — just that the picture is more nuanced than a blanket statement. The SUSTAIN data specifically shows different outcomes in different metabolic phenotypes.